<DOC>
	<DOCNO>NCT02162732</DOCNO>
	<brief_summary>The purpose study test feasibility ( ability do ) experimental technology determine tumor 's molecular makeup . This technology include genomic report base DNA exomes RNA sequence use discover new way understand cancer potentially predict best treatment patient cancer future .</brief_summary>
	<brief_title>Molecular-Guided Therapy Childhood Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Craniopharyngioma</mesh_term>
	<mesh_term>Adamantinoma</mesh_term>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sarcoma , Clear Cell</mesh_term>
	<mesh_term>Neoplasms , Neuroepithelial</mesh_term>
	<mesh_term>Choroid Plexus Neoplasms</mesh_term>
	<criteria>1 . Subjects must prove pediatric cancer confirmation diagnosis time recurrence/progression clinical determination disease know effective curative therapy disease refractory establish proven therapy fit one follow category : Neuroblastoma Patients relapse follow standard care therapy ( high risk patient , patient present age 15 month MYCN amplify , follow ( eligible patient ) highdose chemotherapy follow hematopoietic stem cell transplantation maintenance therapy retinoic acid antibody therapy ) progress standard care therapy nonresponsive/progressive accept curative chemotherapy . Brain Tumors Medulloblastomas ( At relapse standard care therapy [ surgery , chemotherapy and/or radiation ] and/or nonresponsive/progressive accepted curative therapy ) Gliomas ( At relapse standard care therapy [ surgery and/or radiation and/or chemotherapy ] and/or nonresponsive/progressive accepted curative therapy ) Ependymomas ( At relapse standard care therapy [ surgery without radiation ] and/or nonresponsive/progressive accept curative therapy ) Choroid plexus tumor ( At relapse standard care therapy [ surgery ] and/or nonresponsive/progressive accepted curative therapy ) Craniopharyngiomas ( At relapse standard care therapy [ surgery suppressive therapy ] and/or nonresponsive/progressive accepted curative therapy ) Dysembryoplastic neuroepithelial tumor ( DNETs ) ( At relapse standard care therapy [ surgery ] and/or nonresponsive/progressive accepted curative therapy ) Meningiomas ( At relapse standard care therapy [ surgery ] and/or nonresponsive/progressive accepted curative therapy ) Primitive Neuroectodermal Tumors ( PNETs ) ( At relapse standard care therapy [ surgery , chemotherapy , and/or radiation ] and/or nonresponsive/progressive accepted curative therapy ) Germ cell tumor ( At relapse standard care therapy [ surgery , and/or radiation and/or chemotherapy ] and/or nonresponsive/progressive accepted curative therapy ) Rare Tumors : Soft tissue sarcoma Rhabdomyosarcoma ( At relapse standard care therapy [ surgery , and/or radiation , chemotherapy ] and/or nonresponsive/progressive accept curative chemotherapy ) Nonrhabdomyosarcoma ( At relapse standard care therapy [ surgery , and/or radiation , chemotherapy ] and/or nonresponsive/progressive accept curative chemotherapy ) Bone Ewings sarcoma ( At relapse standard care therapy [ surgery , and/or radiation , chemotherapy ] and/or non responsive/progressive accept curative chemotherapy ) Osteosarcoma ( At relapse standard care therapy [ surgery , chemotherapy ] and/or non responsive/progressive accept curative chemotherapy ) Renal Wilms tumor ( At relapse standard care therapy [ surgery , and/or radiation , chemotherapy ] and/or non responsive/progressive accepted chemotherapy ) Renal cell carcinoma ( At relapse standard care therapy [ surgery , chemotherapy ] and/or non responsive/progressive accept curative chemotherapy ) Malignant rhabdoid tumor ( At diagnosis , know curative therapy ) Clear Cell Sarcoma ( At relapse standard care therapy [ radiation , chemotherapy ] and/or non responsive/progressive accept curative chemotherapy ) Germ Cell tumor ( At relapse standard care therapy [ surgery , chemotherapy ] and/or nonresponsive/progressive accept curative chemotherapy ) Liver Tumors ( At relapse standard care therapy [ surgery , chemotherapy ] and/or non responsive/progressive accept curative chemotherapy ) 2 . Subjects must age &gt; 12 month enrollment 3 . Subjects must age ≤ 21 year initial diagnosis 4 . Subjects must measurable disease demonstrate residual abnormal tissue primary metastatic site ( measurable CT MRI ) time biopsy ; tumor must accessible biopsy . In addition , subject bone bone marrow disease expect &gt; 75 % tumor eligible enroll . 5 . Current disease state must one currently know effective therapy 6 . Specimens obtain nonsignificant risk manner solely purpose investigational testing . 7 . Lansky Karnofsky Score must ≥ 50 8 . Subjects without bone marrow metastases must ANC &gt; 750/μl begin treatment . 9 . Subjects CNS disease must stable dose steroid 2 week prior biopsy must progressive hydrocephalus enrollment . 10 . Adequate liver function must demonstrate , define : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) age AND ALT ( SGPT ) &lt; 10 x upper limit normal ( ULN ) age 11 . A negative serum pregnancy test require female participant child bear potential ( ≥13 year age onset menses ) 12 . Both male female postpubertal study subject need agree use one effective birth control method treatment six month treatment stop . These method include total abstinence ( sex ) , oral contraceptive ( `` pill '' ) , intrauterine device ( IUD ) , levonorgestrol implant ( Norplant ) , medroxyprogesterone acetate injection ( Depoprovera shot ) . If one use , contraceptive foam condom recommend . 13 . Informed Consent : All subject and/or legal guardian must sign informed write consent . Assent , appropriate , obtain accord institutional guideline 1 . Subjects receive cytotoxic chemotherapy within last 7 day prior biopsy 2 . Subjects receive radiotherapy primary sample site within last 14 day ( radiation may include treatment decision biopsy ) . 3 . Subjects receive investigational drug concurrently . 4 . Subjects uncontrolled serious infection lifethreatening illness ( unrelated tumor ) 5 . Subjects medical condition , include malabsorption syndrome , mental illness substance abuse , deem Investigator likely interfere interpretation result would interfere subject 's ability sign legal guardian 's ability sign inform consent , subject 's ability cooperate participate study</criteria>
	<gender>All</gender>
	<minimum_age>13 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>